Prot #TAK-788-3001: A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Project: Research project

Project Details

Effective start/end date9/10/209/10/23


  • PPD Investigator Services, LLC (Prot #TAK-788-3001)
  • Millennium Pharmaceuticals, Inc (Prot #TAK-788-3001)